Vaxart Investors Can Tweak Stock Claims Over COVID Vaccine
A group of investors suing Vaxart Inc. can amend their complaint to more clearly allege that the company artificially inflated its stock price through a press release with a deceptive headline...To view the full article, register now.
Already a subscriber? Click here to view full article